Home > Oncology > Tumor marker of bone metastasis in ER+ breast cancer identified

Tumor marker of bone metastasis in ER+ breast cancer identified


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
Bone
Reuters Health - 02/12/2020 - Upregulation of trefoil factor-1 (TFF1) in primary estrogen-receptor (ER)-positive breast cancer may help identify women at high-risk of bone metastasis, according to a study from Italy. "This could help clinicians in the identification of patients who likely can develop bone metastasis and who could benefit from personalized treatments and follow-up strategies to prevent metastatic disease," researchers write in the journal Bone. "Bone is one of the most preferred sites of metastatic spread from different cancer types, including breast cancer. Despite advances in the diagnosis, the identification of patients at high-risk of bone recurrence is still an unmet clinical need," write Dr. Laura Mercatali of the Scientific Institute of Romagna for the Study and Treatment of Tumors (IRST), in Meldola, and colleagues. To identify a tumor-derived factor associated with risk of bone metastasis, the researchers compared gene and protein exp...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on